Back to top Open menu arrow
Purchase PDF Reprints

The Journal of
Clinical Psychiatry
Members only

The Journal of Clinical Psychiatry

Original Research September 21, 2026

An Open-Label, Dose-Escalation Trial of Psilocybin-Assisted Therapy for Bipolar II Depression

; ; ; ; ; ; ; ; ; ; ; ; ;

J Clin Psychiatry 2026;87(4):25m16227

Abstract

Objective: Individuals with bipolar II disorder (BD-II) and depression face limited treatment options and are often excluded from psilocybin therapy trials due to concerns about precipitating mania or psychosis. The objective of this study was to evaluate the safety, tolerability, and preliminary efficacy of psilocybin therapy in individuals with BD-II and depression.

Methods: We conducted an open-label, single-arm pilot trial from 2022–2025 in which 14 participants with BD-II depression, diagnosed using adapted criteria requiring ≥2 consecutive days of hypomanic symptoms, received 10 mg of psilocybin, followed by 25 mg if symptoms persisted. Participants completed psychotherapy before, during, and after psilocybin sessions and were proactively monitored for adverse events. Depression and quality of life were assessed using the Montgomery-Asberg Depression Rating Scale (MADRS; primary end point 21 days after each participant’s final administration session) and the Quality of Life in Bipolar Disorder Questionnaire (QoL-BD), alongside exploratory measures.

Results: Psilocybin was well tolerated, with only transient increases in heart rate and blood pressure and no serious adverse events. Common side effects included mild-to-moderate anxiety, nausea, and headache. Three participants experienced notable psychiatric events (suicidal ideation or hypomania), which resolved with support. Following the 10 mg session, MADRS scores improved significantly (−12.7 [2.7], P<.001), with 4 participants (28.5%) meeting remission criteria and therefore not proceeding to the 25 mg session; 9 participants received the 25 mg dose. Among those who received the 25 mg dose, MADRS scores improved significantly 21 days following 25 mg (−18.6 [3.1], P<.001). QoL-BD scores also improved at 90 days following the final dose (31.2 [10.2], P=.004).

Conclusion: These findings suggest that psilocybin therapy may be safe, tolerable, and preliminarily efficacious for treating depression in BD-II, but randomized controlled trials are needed to confirm efficacy and optimize protocols.

Trial Registration: ClinicalTrials.gov identifier: NCT05065294

J Clin Psychiatry 2026;87(4):25m16227

Author affiliations are listed at the end of this article.

Also from JCP

Safety and Efficacy of Maintenance Treatment with Aripiprazole Once-Monthly in Black/African American Adults With Bipolar I Disorder Outcomes and Practice Patterns of LAI Versus Oral Antipsychotics Among Patients With Bipolar I Disorder in the US Oral Glutamatergic Modulation with Dextromethorphan and Piracetam for Refractory Bipolar Disorder With OCD

From the Editors

New Series The JCP Podcast A one-year follow-up to one of the first placebo-controlled schizophrenia trials produced a startling result: some placebo-treated patients seemed to do better, until closer scrutiny exposed how trial design and extra attention can distort outcomes. Six decades later, the bigger takeaway still lands hard: schizophrenia care is a team sport built on medication, but no single intervention gets patients to meaningful recovery on its own.

Members Only Content

This full article is available exclusively to Professional tier members. Subscribe now to unlock the HTML version and gain unlimited access to our entire library plus all PDFs. If you're already a subscriber, please log in below to continue reading.

Subscribe Now

Already a member? Log in

  1. Grande I, Berk M, Birmaher B, et al. Bipolar disorder. Lancet. 2016;387(10027):1561–1572. PubMed CrossRef
  2. Karanti A, Kardell M, Joas E, et al. Characteristics of bipolar I and II disorder: a study of 8766 individuals. Bipolar Disord. 2020;22(4):392–400. PubMed CrossRef
  3. Swartz HA, Suppes T. Bipolar II disorder: understudied and underdiagnosed. Focus (Am Psychiatr Publ). 2023;21(4):354–362. PubMed CrossRef
  4. Carhart-Harris R, Giribaldi B, Watts R, et al. Trial of psilocybin versus escitalopram for depression. N Engl J Med. 2021;384(15):1402–1411. PubMed CrossRef
  5. Carhart-Harris RL, Bolstridge M, Rucker J, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. 2016;3(7):619–627. PubMed CrossRef
  6. Goodwin GM, Aaronson ST, Alvarez O, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. New Engl J Med. 2022;387(18):1637–1648. PubMed CrossRef
  7. Raison CL, Sanacora G, Woolley J, et al. Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial. JAMA. 2023;330(9):843–853. PubMed CrossRef
  8. Downey AE, Bradley ER, Lerche AS, et al. A plea for nuance: should people with a family history of bipolar disorder be excluded from clinical trials of psilocybin therapy?. Psychedelic Med (New Rochelle). 2024;2(2):61–73. PubMed CrossRef
  9. Gard DE, Pleet MM, Bradley ER, et al. Evaluating the risk of psilocybin for the treatment of bipolar depression: a review of the research literature and published case studies. J Affect Disord Rep. 2021;6:100240. CrossRef
  10. Morton E, Sakai K, Ashtari A, et al. Risks and benefits of psilocybin use in people with bipolar disorder: an international web-based survey on experiences of “magic mushroom” consumption. J Psychopharmacol. 2023;37(1):49–60. PubMed CrossRef
  11. Aaronson ST, van der Vaart A, Miller T, et al. Single-dose synthetic psilocybin with psychotherapy for treatment-resistant bipolar type II major depressive episodes: a nonrandomized open-label trial. JAMA Psychiatry. 2024;81(6):555–562. PubMed CrossRef
  12. Meshkat S, Kaczmarek E, Doyle Z, et al. Psilocybin-assisted psychotherapy for treatment-resistant depression in bipolar II disorder. Psychedelic Med (New Rochelle). 2025;3(1):53–58. PubMed CrossRef
  13. Rosenblat JD, Meshkat S, Doyle Z, et al. Psilocybin-assisted psychotherapy for treatment resistant depression: a randomized clinical trial evaluating repeated doses of psilocybin. Med. 2024;5(3):190–200.e5. PubMed CrossRef
  14. Hinkle JT, Graziosi M, Nayak SM, et al. Adverse events in studies of classic psychedelics: a systematic review and meta-analysis. JAMA Psychiatry. 2024;81(12):1225–1235. PubMed CrossRef
  15. Vaughan B, Goldstein MH, Alikakos M, et al. Frequency of reporting of adverse events in randomized controlled trials of psychotherapy vs. psychopharmacotherapy. Compr Psychiatry. 2014;55(4):849–855. PubMed CrossRef
  16. Van Elk M, Fried EI. History repeating: a roadmap to address common problems in psychedelic science. PsyArXiv. 2023. doi:10.31234/osf.io/ak6gx. CrossRef
  17. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–389. PubMed CrossRef
  18. First MB. Structured Clinical Interview for the DSM (SCID). In: The Encyclopedia of Clinical Psychology. John Wiley & Sons, Ltd; 2015:1–6.
  19. Suppes T, Dennehy EB, Gibbons EW. The longitudinal course of bipolar disorder. J Clin Psychiatry. 2000;61(Suppl 9):23–30. PubMed
  20. Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266–1277. PubMed CrossRef
  21. Mohammadi Z, Pourshahbaz A, Poshtmashhadi M, et al. Psychometric properties of the Young Mania Rating Scale as a mania severity measure in patients with bipolar I disorder. J Pract Clin Psychol. 2018;6(3):175–182.
  22. Kay SR, Opler LA, Lindenmayer JP. The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br J Psychiatry. 1989;155(S7):59–65. PubMed
  23. Morin CM, Belleville G, Bélanger L, et al. The Insomnia Severity Index: psychometric indicators to detect insomnia cases and evaluate treatment response. Sleep. 2011;34(5):601–608. PubMed CrossRef
  24. Morton E, Murray G, Yatham LN, et al. The Quality of Life in Bipolar Disorder (QoL.BD) questionnaire a decade on – a systematic review of the measurement of condition-specific aspects of quality of life in bipolar-disorder. J Affect Disord. 2021;278:33–45. PubMed CrossRef
  25. Younger J, Gandhi V, Hubbard E, et al. Development of the Stanford Expectations of Treatment Scale (SETS): a tool for measuring patient outcome expectancy in clinical trials. Clin Trials. 2012;9(6):767–776. PubMed CrossRef
  26. Blevins CA, Weathers FW, Davis MT, et al. The Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5): development and initial psychometric evaluation. J Trauma Stress. 2015;28(6):489–498. PubMed CrossRef
  27. Fraley RC, Waller NG, Brennan KA. An item response theory analysis of self-report measures of adult attachment. J Personality Soc Psychol. 2000;78(2):350–365. PubMed CrossRef
  28. Murphy A, Steele M, Dube SR, et al. Adverse Childhood Experiences (ACEs) questionnaire and Adult Attachment Interview (AAI): implications for parent child relationships. Child Abuse Negl. 2014;38(2):224–233. PubMed CrossRef
  29. Roseman L, Haijen E, Idialu-Ikato K, et al. Emotional breakthrough and psychedelics: validation of the Emotional Breakthrough Inventory. J Psychopharmacol. 2019;33(9):1076–1087. PubMed CrossRef
  30. Barrett FS, Johnson MW, Griffiths RR. Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. J Psychopharmacol. 2015;29(11):1182–1190. PubMed CrossRef
  31. Barrett FS, Bradstreet MP, Leoutsakos JMS, et al. The Challenging Experience Questionnaire: characterization of challenging experiences with psilocybin mushrooms. J Psychopharmacol. 2016;30(12):1279–1295. PubMed CrossRef
  32. Bovin MJ, Marx BP, Weathers FW, et al. Psychometric properties of the PTSD Checklist for Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (PCL-5) in veterans. Psychol Assess. 2016;28(11):1379–1391. PubMed CrossRef
  33. Picardi A, Pallagrosi M, Fonzi L, et al. Attachment in patients with bipolar and unipolar depression: a comparison with clinical and non-clinical controls. Clin Pract Epidemiol Ment Health. 2019;15:143–152. PubMed CrossRef
  34. Khan AJ, Bradley E, O’Donovan A, et al. Psilocybin for trauma-related disorders. In: Barrett FS, Preller KH, eds. Disruptive Psychopharmacology. Springer International Publishing; 2022:319–332.
  35. McGowan NM, Rucker JJ, Yehuda R, et al. Investigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder: a nonrandomized open-label clinical trial. J Psychopharmacol. 2025:2698811251362390.
  36. Anderson BT, Danforth A, Daroff PR, et al. Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: an open-label safety and feasibility pilot study. EClinicalMedicine. 2020;27:100538. PubMed CrossRef
  37. Watts BV, Schnurr PP, Mayo L, et al. Meta-analysis of the efficacy of treatments for posttraumatic stress disorder. J Clin Psychiatry. 2013;74(6):e541–e550. PubMed CrossRef
  38. Taylor P, Rietzschel J, Danquah A, et al. Changes in attachment representations during psychological therapy. Psychother Res. 2015;25(2):222–238. PubMed CrossRef
  39. Szigeti B, Weiss B, Rosas FE, et al. Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression. Psychol Med. 2024:1–8. CrossRef
  40. Melhuish Beaupre LM, Tiwari AK, Gonçalves VF, et al. Antidepressant-associated mania in bipolar disorder: a review and meta-analysis of potential clinical and genetic risk factors. J Clin Psychopharmacol. 2020;40(2):180–185. PubMed CrossRef
  41. Goodwin GM, Croal M, Feifel D, et al. Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication. Neuropsychopharmacology. 2023;48(10):1492–1499. PubMed CrossRef
  42. Haft SL, Downey AE, Raymond-Flesch M, et al. A systematic review of participant diversity in psychedelic-assisted psychotherapy trials. Psychiatry Res. 2025;345:116359. PubMed CrossRef

About the Authors

Buy PDF for $40

Please sign in or purchase this PDF for $40.

The Journal of Clinical Psychiatry June 2026 cover with featured article titles

Vol 87 • 2026 • Number 2

Read the Current Issue

Original Research

CBT following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention: The CBT-ENDURE Randomized Trial

Original Research

Neuropsychiatric Symptom Clusters and Brain Structure in Alzheimer’s Disease

Systematic Review

Thirty Years of the Diagnostic Criteria for Psychosomatic Research

Original Research

Efficacy of Olanzapine/Samidorphan on Negative Symptoms

Original Research

Comparing Risk Prediction for Suicide Attempts and Deaths After Emergency Department Visits

Clinical and Practical Psychopharmacology

Insomnia, Sleep, and the Use of Sedative-Hypnotic Drugs: Practical Notes
View current Issue

Learn More About Ketamine and Psychedelics

Listen to the Podcast
The Journal of Clinical Psychiatry podcast cover with Benjamin Brody, MD

Subscribe to read
more articles

Subscribe